Compare Abeona Therapeutics Inc (ABEO) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Global X NASDAQ 100 Covered Call ETF trades at $18.16. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Global X NASDAQ 100 Covered Call ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | QYLD | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.45 | $18.52 |
52-Week Low | $4.17 | $16.46 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
QYLD trades at $18.18, up 0.17% with a bullish technical signal from moving averages but bearish oscillators. The ETF maintains its covered call strategy, generating consistent monthly dividends, though financial ratios are unavailable. Recent news highlights both the appeal of its 11.67% yield and concerns about long-term underperformance versus the Nasdaq-100.
Outlook: High income potential in sideways markets, but capital appreciation is limited. Risks include erosion of NAV during bull markets and competition from lower-fee alternatives. Suitable for income-focused investors willing to sacrifice growth for yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
